ESTRO 2020 Abstract book

S708 ESTRO 2020

chemotherapy administration, patients were treated with QUAD SHOT regimen of 14.4 Gy in 4 fractions with one fraction per day for 4 days without treatment interruptions in between from day 1 to day 4 via 3DCRT technique. After 3 weeks, patients who had palliation of symptoms and improvement in quality of life were considered for the next session of chemo-radiation and patients who had no benefit or severe reactions were not given further chemo- radiation and these patients were managed with best supportive care. Patients are followed up post 2 nd cycle of Quad shot at 3rd week, followed by monthly upto 3 months and every 3 months upto 1 year and assessed for palliation of symptoms and quality of life with validated questionnaire of EORTC QLQ-H&N 35 (English and kannada version), toxicity with RTOG toxicity grading and CTCAE Version 4.3. Results The present study revealed that QUAD SHOT regimen was able to produce palliation of symptoms and improvement in QoL in 80% of the patients and it was sustained upto 3 months with a median overall survival of 8 ± 0.411 months. However post phase 1, one patient reported Grade IV toxicity and two patients reported Grade IV toxicity after 2 nd phase RT and were managed with best supportive care

Toxicity Grades of 65 patients in this study

Grade 0

Grade 1

Grade 2

Grade 3

Grade 4

phase 1 phase 2

54 54 59 52 33 21 12

0 0 4 2 0 0 0

9 5 0 2 4 3 2

1 3 0 0 0 0 0

1 2 0 0 0 0 0

2nd month 3rd month 6th month 9th month 12th month

Conclusion In patients with cancers of the head and neck not suitable for curative treatment and with limited life expectancy, the QUAD SHOT regimen with concurrent radiosensitizing chemotherapy offers an overall high palliative response rate and is well tolerated. It is an effective palliative approach that minimizes the burden of longer protracted courses of treatment. The short duration of the treatment was favored by the outstation patients and their attendants. It may be concluded that this short course of therapy is an effective tool for palliation of symptoms, improving quality of life with acceptable toxicity and merits a larger randomized trial. PO-1255 Prognostic factors in brain metastases from breast cancer treated with Cyberknife G. Riva 1 , A. Ferrari 1 , I. Cavallo 1 , L. Bergamaschi 1 , S. Durante 1 , G. Piperno 1 , S. Vigorito 2 , F. Cattani 2 , R. Orecchia 3 , B.A. Jereczek-Fossa 1 1 Istituto Europeo di Oncologia - IEO, Radiotherapy, MIlan, Italy ; 2 Istituto Europeo di Oncologia - IEO, Medical Physics, MIlan, Italy ; 3 Istituto Europeo di Oncologia - IEO, Scientific Directorate, MIlan, Italy Purpose or Objective The objective of this study was to explore factors associated with local control (LC), distant intra-cranial control (DBC) and overall survival (OS) in a mono institutional experience in the stereotactic radiosurgery (SRS) of patients with brain metastases from breast cancer.